Starting antiretroviral therapy with a ritonavir (Norvir)-boosted protease inhibitor resulted in a higher incidence of chronic kidney disease (CKD), whether or not the regimen included tenofovir disoproxil fumarate (TDF, Viread), according to a recen...
Multiple dosing with doravirine does not change the plasma pharmacokinetics of a single dose of ethinyl estradiol or levonorgestrel to a clinically important extent, according to data shown at the 6th International Workshop on HIV and Women.
A team in Chicago recently reported an interaction between cobicistat and the transplant medicine tacrolimus (Advagraf, Prograf) in a person taking Stribild, and cautioned others to be mindful of the potential for interaction between these drugs.
Taking darunavir/cobicistat (Prezcobix) with a new HIV drug known as BMS-663068, which is currently being studied, was safe and did not cause any serious reactions in two studies.
Antiretroviral combinations including a protease inhibitor led to undetectable viral loads more often when people took their pills on time at least 95% of the time than when they took their pills less often.
What are the hottest developments in HIV clinical science over the past year? Physician-researcher Adaora Adimora, M.D., M.P.H., brought us a brief tour of key highlights at the start of the IDWeek 2015 medical conference in San Diego.
Unintended Pregnancies With Levonorgestrel Implant Due to Drug Interactions With Efavirenz-Based Antiretroviral Therapy
Three unintended pregnancies in women with levonorgestrel sub-dermal implants, receiving efavirenz-based antiretroviral therapy in a pharmacokinetic study, were reported in a late breaker presentation at CROI 2015.
Each year we see new developments in HIV that improve the lives of those living with the disease and make it easier for providers to care for patients. We asked some of the leading experts what development this year they thought would have the biggest …
HIV treatment remains far from perfect, and there are still seats at the table available for improved antiretrovirals. Paul Sax, M.D., provides an update on several of the most noteworthy candidates currently in development.